Fluticasone
From Free net encyclopedia
Guanaco (Talk | contribs)
Reverted edits by [[Special:Contributions/207.229.174.14|207.229.174.14]] ([[User talk:207.229.174.14|talk]]) to last version by Light current
Next diff →
Current revision
|
Image:Fluticasone propionate.png | |
| 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17- (1-oxopropoxy)-androsta-1,4-diene-17-carbothioic acid (6α,11β,16α,17α)- S-(fluoromethyl) ester | |
| CAS number 90566-53-3 or 80474-14-2 (with proprionate) | ATC code D07AC17, R01AD08, R03BA05 |
| Chemical formula | C22-H27-F3-O4-S or C25-H31-F3-O5-S (with proprionate) |
| Molecular weight | 444.511 or 500.575 (with proprionate) |
| Bioavailability | 0.51% (Intranasal) |
| Metabolism | Intranasal- hepatic cytochrome p450,3A4 |
| Elimination half-life | 7.8 hours |
| Excretion | renal |
| Pregnancy category | Category C for Intranasal and Inhaled |
| Legal status | ? |
| Routes of administration | Intranasal, Inhaled, Topical Cream or Ointment |
Fluticasone proprionate is a glucocorticoid often prescribed as treatment for asthma and allergic rhinitis. It is marketed with the brand name Flixotide® and Flixonase® by Allen & Hanburys and Flovent® and Flonase® by GlaxoSmithKline.
How it works
The precise mechanisms of glucocorticoid action in asthma are unknown. Inflammation is recognized as an important component in the pathogenesis of asthma. Glucocorticoids have been shown to inhibit multiple cell types (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and mediator production or secretion (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in the asthmatic response. These anti-inflammatory actions of glucocorticoids may contribute to their efficacy in asthma. Typically, however, the action on the cells affected requires several days. Therefore, inhaled steroids are not used for immediate relief of asthma, but instead as preventive and maintenance therapy.
Clinical trials
This listing is NOT complete and should NOT be construed as support for treatment decisions. See also PubMed clinical manuscripts referring to fluticasone
- Burge, P.S.; Calverley, P.M.; Jones, P.W.; Spencer, S.; Anderson, J.A.; and Maslen T.K. (2000). Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. British Medical Journal 320 (7245), 1297-1303. PMID 10807619.
- Paggiaro, P.L.; Dahle, R.; Bakran, I.; Frith, L.; Hollingworth, K.; and Efthimiou, J. (1998). Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. The Lancet 351 (9105), 773-780. PMID 9519948.
- both support a positive outcome for use of fluticasone in patients with chronic obstructive pulmonary disease, also referred to as COPD